Full TitleA Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression (GOG-0283)
Five percent of gynecologic cancers are clear cell cancers. About half of clear cell cancers affecting the ovaries or endometrium (uterine lining) have a faulty version of a protein called BAF250a. Normal BAF250a keeps healthy cells from becoming cancer cells. BAF250s that does not function well may lead to cancer growth.
Laboratory studies have shown that dasatinib is effective against ovarian and endometrial cancer cells that have an altered version of the BAF250a protein. In this Gynecologic Oncology Group study, researchers are evaluating the safety and effectiveness of dasatinib in women with clear cell cancer of the ovaries, fallopian tubes, peritoneum, or endometrium whose cancer has persisted or returned despite standard therapy.
Dasatinib is already approved for treating a type of leukemia; its use in this study is considered investigational. It is a pill that is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have clear cell cancer of the ovaries, fallopian tubes, peritoneum, or endometrium that has persisted or returned despite standard therapy.
- Patients may have had up to three prior regimens of chemotherapy, with at least one of them including a platinum-containing drug.
- At least 3 weeks must have passed since completion of prior chemotherapy or radiation therapy and entry into the study.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.